Cambridge, MA – September 9, 2026

Tinos Therapeutics has been selected to present at Boston Biotech Investor Day (BBID) 2026, joining a cohort of biotech startups to pitch to investors and industry leaders across the Boston ecosystem. Chosen from a competitive pool of 150 global applicants, Tinos Therapeutics will be one of 20 companies presenting this year.

Now in its third year, BBID brings together the region's most promising early-stage biotech companies with investors and pharmaceutical partners for a day of pitches, panel discussions, and networking among hundreds of expected attendees. The event is intended for companies and investors focused on the seed round through Series A.

At BBID 2026, Tinos Therapeutics will introduce its RNA-modification-based small molecule program aimed at addressing critical unmet needs, including glioblastoma. The presentation offers an opportunity to connect with potential partners who can help accelerate the therapy's path to patients.

This year, BBID is co-hosted by LabCentral, BioLabs, MassBio, the Termeer Institute, and The Engine, and will be held September 22, 2026, in Cambridge, Massachusetts.

‍